Avalo Therapeutics Inc AVTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
-
Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress
-
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
-
Avalo Therapeutics to Participate in Upcoming Investor Conferences
-
Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates
Trading Information
- Previous Close Price
- $7.45
- Day Range
- $6.53–7.50
- 52-Week Range
- $6.53–24.27
- Bid/Ask
- $6.74 / $7.14
- Shares Outstanding
- 53.63M
- Market Cap
- $371.66M
- Volume/Avg
- 5M / 1M
Key Statistics
- Price/Earnings (Normalized)
- 1.60
- Price/Sales
- 2,822.81
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 33
- Website
- https://www.avalotx.com
Valuation
|
Metric
|
AVTX
|
|---|---|
Price/Earnings (Normalized) | 1.60 |
Price/Book Value | 0.82 |
Price/Sales | 2,822.81 |
Price/Cash Flow | — |
Price/Earnings
AVTX
Financial Strength
|
Metric
|
AVTX
|
|---|---|
Quick Ratio | 18.94 |
Current Ratio | 19.31 |
Interest Coverage | — |
Quick Ratio
AVTX
Profitability
|
Metric
|
AVTX
|
|---|---|
Return on Assets (Normalized) | −39.54% |
Return on Equity (Normalized) | −47.62% |
Return on Invested Capital (Normalized) | −50.30% |
Return on Assets
AVTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|%q^$M& | LOCK|tN&jh | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Ms@S%>! | LOCK|Fr<d! | $83B | |||
| Moderna Inc
MRNA
| LOCK|WM#t@F! | LOCK|!bL | $80B | |||
| argenx SE ADR
ARGX
| LOCK|Fx@Q!V< | LOCK|Ks% | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|d&&y&TV | LOCK|^f% | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|m?&WGm | LOCK|?rY^ | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|LMK^f^?? | LOCK|$%vdz | $28B | |||
| Incyte Corp
INCY
| LOCK|#q&ZRN | LOCK|?V | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|X@$@#Z | LOCK|&!f | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|XVwg$MC | LOCK|!C | $14B |
United States